Krista Rossi

The FDA has approved sumatriptan nasal spray (Tosymra, Promius Pharma) for the acute treatment of migraine with or without aura in adults.

One hundred percent of patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response at 12 weeks post treatment with 8 weeks of glecaprevir/pibrentasvir treatment.

New data presented at the 2018 ACR/ARHP Annual Meeting shows that the treatment regimens for many patients are not being changed to reach a “treat-to-target” goal for low disease activity.

Brain inflammation caused by critical illness and infection may lead to the observed reduction in brain volume.